Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02778516 · ClinicalTrials.gov registry record · NA
Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT
A NA study of ESRD, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT02778516: Completed NA study of ESRD, sponsored by University of Pennsylvania.
NCT02778516 is a NA study of ESRD that has completed, run by University of Pennsylvania. The registered enrollment target is 42 participants, below the 138-participant average among 13 other ESRD trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02778516, a NA study of ESRD, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
Dietary sodium intake independently increases the risk of mortality in end stage renal disease (ESRD). It plays a significant role in hypertension, hypervolemia, and left ventricular hypertrophy (LVH), and blunts the effectiveness of hypertensive agents. In addition, the hypervolemia associated with excessive dietary sodium intake results in the need for more intense fluid removal during dialysis (ultrafiltration), resulting in symptoms such as pain, cramps, hypotension, nausea, and vomiting during hemodialysis (HD) treatment sessions. Although sodium restriction is a universal recommendation for ESRD management, the National Kidney Foundation (NKF) recommendation of 2400 mg/day is consensus-based per the Dietary Approaches to Stop Hypertension (DASH) studies, not an evidence-based recommendation from data derived from a dialysis population. In addition, The Dietary Guidelines for Americans 2010, recommend further restriction of dietary sodium intake to 1500 mg per day for persons with hypertension and/or kidney disease, middle-aged and older adults, and African Americans, though there is also little empiric evidence to support this recommendation in the general population and none in the dialysis population. Therefore, it remains to be demonstrated that a diet with such sodium restrictions is attainable, sustainable, safe or beneficial. The investigators propose a double blind randomized controlled design investigation to examine the feasibility of assessing the effects of three levels of sodium intake (ambient, 2400 mg/d, 1500 mg/d) on the hemodialysis (HD) participant symptom profile, and to compare the effect of hemodialysis-specific variables on participant symptom profile during dialysis as well as to explore the role of body fluid composition using bioimpedance (BIA) measurements among the three sodium-restricted groups as a marker of sodium restriction efficacy.
Primary Outcome
IDWG is defined as the difference in weight in kilograms between measurement at time 1 (immediately following HD) and time 2 (immediately prior to the next HD session).4 Weights will be obtained in the aforementioned fashion in the CTRC, and calculated by the CTRC nursing core staff. The PI will train CTRC personnel on IDWG calculations.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Sodium Restriction
Study Locations (1)
Pennsylvania
- University of Pennsylvania School of Nursing - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-08 |
| Phase | NA |
What the finished NCT02778516 record still lists
NCT02778516 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 138-participant average among 13 other ESRD trials with a reported enrollment target (70% lower).
The record links to 1 condition, with ESRD appearing as the primary indexed condition, and to 1 intervention - of which Sodium Restriction is the first listed.
NCT02778516 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02778516 about?
NCT02778516 is a clinical study titled "Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT". Dietary sodium intake independently increases the risk of mortality in end stage renal disease (ESRD). It plays a significant role in hypertension, hypervolemia, and left ventricular hypertrophy (LVH), and blunts the effectiveness of hypertensive agents. In addition, the hypervolemia associated with...
What is the current status of trial NCT02778516?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2014-08. Estimated completion is 2016-08.
What conditions does trial NCT02778516 study?
This clinical trial studies the following conditions: ESRD.
What interventions are being tested in trial NCT02778516?
The interventions under investigation include: Sodium Restriction (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02778516?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02778516 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ESRD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02778516's enrollment target sits among peer trials
42 11th of 13 higher than 3 of 13 other ESRD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ESRD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Repletion of Ergothioneine in Patients With Kidney Failure
RECRUITING · NA
-
Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR
COMPLETED · NA
-
Comparison of Different Glucose Concentrations in Dialysate of Hemodialysis Patients
COMPLETED · NA
-
Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia